The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its legacy within the broader industry now presents questions about long-term returns . Copycat versions are eroding market share, leading to anxieties that investing in companies significantly dependent to Viagra's former influence could be a dan